(603858)"Shandong Buchang Pharmaceuticals Co., Ltd."Report for Q3 2026
Filed with SSE · Stock code 603858 · · 9 pages · Chinese
Summary by 6ix AI
The report indicates that the company's total revenue and net profit have experienced fluctuations compared to the previous year. It also highlights that the financial statements have not been audited, and the board assures the accuracy and completeness of the report's content.
Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries
Shandong Buchang Pharmaceuticals Co., Ltd. on 6ix
Earlier from Shandong Buchang Pharmaceuticals
- (603858)"Shandong Buchang Pharmaceuticals Co., Ltd."Announcement on Receipt of the Drug Clinical Trial Approval Notice by Controlled Subsidiaries
- (603858)"Shandong Buchang Pharmaceuticals Co., Ltd."Announcement on Providing Guarantee for Wholly-owned Subsidiary
- (603858)"Shandong Buchang Pharmaceuticals Co., Ltd."Announcement on Implementation of Dividend Distribution for the First Half of 2026
- (603858)"Shandong Buchang Pharmaceuticals Co., Ltd."Announcement on Progress of Proposed External Investment by Controlled Subsidiary for Establishment of Wholly-owned Subsidiary
- (603858)"Shandong Buchang Pharmaceuticals Co., Ltd."Announcement on Approval of Marketing Authorization for Qianlie Shutong Capsules in Indonesia
Later from Shandong Buchang Pharmaceuticals
All Shandong Buchang Pharmaceuticals news releasesFollow Shandong Buchang Pharmaceuticals into a list and get an email when it puts out news.
Follow Shandong Buchang Pharmaceuticals